Healthcare

Mirum Pharmaceuticals focuses on rare liver diseases and has built a fast-growing commercial franchise led by LIVMARLI. Revenue expansion has been impressive, and new indications plus international reach could deepen its position in a specialized market.

MiniMed Group focuses on diabetes technology, combining insulin delivery, glucose monitoring, and recurring supplies. Revenue is expanding faster than many peers, and the market opportunity is durable, making the company’s path toward scale and stronger margins worth a closer look.

Liquidia Technologies is evolving into a focused commercial biotech built around YUTREPIA for pulmonary hypertension. Revenue growth has accelerated sharply, margins have turned positive, and recent regulatory progress has made the business far more concrete than in its earlier development years.

Lantheus is a profitable medical imaging and radiopharmaceutical company best known for prostate cancer diagnostics. Strong cash flow, high margins, and a growing oncology platform make it a business worth examining closely for long-term market watchers.

Veradermics is a clinical-stage dermatology biotech centered on hair-loss treatment, a large market with clear unmet need. Its focused strategy and accelerating R&D effort make upcoming pipeline milestones especially important for understanding its long-term potential.

Ligand Pharmaceuticals earns royalties, licensing income, and Captisol-related revenue from a broad portfolio of partnered drug assets. Recent growth, strong margins, and improving cash flow make its royalty-platform model especially worth a closer look.

LivaNova develops medical devices for cardiac surgery and neuromodulation, with improving revenue, stronger cash generation, and a cleaner balance sheet. Its focused portfolio and recent margin recovery make the company’s next phase worth a closer look.